1
|
Schneider AK, Domingos-Pereira S, Cesson V, Polak L, Fallon PG, Zhu J, Roth B, Nardelli-Haefliger D, Derré L. Type 2 innate lymphoid cells are not involved in mouse bladder tumor development. Front Immunol 2024; 14:1335326. [PMID: 38283350 PMCID: PMC10820705 DOI: 10.3389/fimmu.2023.1335326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Accepted: 12/20/2023] [Indexed: 01/30/2024] Open
Abstract
Therapies for bladder cancer patients are limited by side effects and failures, highlighting the need for novel targets to improve disease management. Given the emerging evidence highlighting the key role of innate lymphoid cell subsets, especially type 2 innate lymphoid cells (ILC2s), in shaping the tumor microenvironment and immune responses, we investigated the contribution of ILC2s in bladder tumor development. Using the orthotopic murine MB49 bladder tumor model, we found a strong enrichment of ILC2s in the bladder under steady-state conditions, comparable to that in the lung. However, as tumors grew, we observed an increase in ILC1s but no changes in ILC2s. Targeting ILC2s by blocking IL-4/IL-13 signaling pathways, IL-5, or IL-33 receptor, or using IL-33-deficient or ILC2-deficient mice, did not affect mice survival following bladder tumor implantation. Overall, these results suggest that ILC2s do not contribute significantly to bladder tumor development, yet further investigations are required to confirm these results in bladder cancer patients.
Collapse
Affiliation(s)
- Anna K Schneider
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Sonia Domingos-Pereira
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Valérie Cesson
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Lenka Polak
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Padraic G Fallon
- School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| | - Jinfang Zhu
- Molecular and Cellular Immunoregulation Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Beat Roth
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Denise Nardelli-Haefliger
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Laurent Derré
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| |
Collapse
|
2
|
Derré L, Lucca I, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias SC, Dartiguenave F, Masnada A, Teixeira-Pereira C, Benmerzoug S, Chevalier MF, Domingos-Pereira S, Nguyen S, Polak L, Schneider AK, Jichlinski P, Roth B, Nardelli-Haefliger D. Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential. J Immunother Cancer 2023; 11:e008020. [PMID: 38101861 PMCID: PMC10729085 DOI: 10.1136/jitc-2023-008020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/30/2023] [Indexed: 12/17/2023] Open
Abstract
BACKGROUND Standard of care treatment of non-muscle invasive bladder cancer (NMIBC) with intravesical Bacillus Calmette Guérin (BCG) is associated with side effects, disease recurrence/progression and supply shortages. We recently showed in a phase I trial (NCT03421236) that intravesical instillation in patients with NMIBC with the maximal tolerated dose of Ty21a/Vivotif, the oral vaccine against typhoid fever, might have a better safety profile. In the present report, we assessed the immunogenicity of intravesical Ty21a in patients of the clinical trial that had received the maximal tolerated dose and compared it with data obtained in patients that had received standard BCG. METHODS Urinary cytokines and immune cells of patients with NMIBC treated with intravesical instillations of Ty21a (n=13, groups A and F in NCT03421236) or with standard BCG in a concomitant observational study (n=12, UROV1) were determined by Luminex and flow cytometry, respectively. Serum anti-lipopolysaccharide Typhi antibodies and circulating Ty21a-specific T-cell responses were also determined in the Ty21a patients. Multiple comparisons of different paired variables were performed with a mixed-effect analysis, followed by Sidak post-test. Single comparisons were performed with a paired or an unpaired Student's t-test. RESULTS As compared with BCG, Ty21a induced lower levels of inflammatory urinary cytokines, which correlated to the milder adverse events (AEs) observed in Ty21a patients. However, both Ty21a and BCG induced a Th1 tumor environment. Peripheral Ty21a-specific T-cell responses and/or antibodies were observed in most Ty21a patients, pointing the bladder as an efficient local immune inductive site. Besides, Ty21a-mediated stimulation of unconventional Vδ2 T cells was also observed, which turned out more efficient than BCG. Finally, few Ty21a instillations were sufficient for increasing urinary infiltration of dendritic cells and T cells, which were previously associated with therapeutic efficacy in the orthotopic mouse model of NMIBC. CONCLUSIONS Ty21a immunotherapy of patient with NMIBC is promising with fewer inflammatory cytokines and mild AE, but induction of immune responses with possible antitumor potentials. Future phase II clinical trials are necessary to explore possible efficacy of intravesical Ty21a.
Collapse
Affiliation(s)
- Laurent Derré
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Ilaria Lucca
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Valérie Cesson
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Perrine Bohner
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Francois Crettenand
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Sonia-Cristina Rodrigues-Dias
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Florence Dartiguenave
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Audrey Masnada
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Carla Teixeira-Pereira
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Sulayman Benmerzoug
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Mathieu F Chevalier
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Sonia Domingos-Pereira
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Sylvain Nguyen
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Lenka Polak
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Anna K Schneider
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Patrice Jichlinski
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Beat Roth
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| | - Denise Nardelli-Haefliger
- Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
| |
Collapse
|
3
|
Nguyen S, Chevalier MF, Benmerzoug S, Cesson V, Schneider AK, Rodrigues-Dias SC, Dartiguenave F, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments. J Immunother Cancer 2022; 10:jitc-2022-004880. [PMID: 36002184 PMCID: PMC9413168 DOI: 10.1136/jitc-2022-004880] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/02/2022] [Indexed: 11/06/2022] Open
Abstract
Background Bladder cancer is an important public health concern due to its prevalence, high risk of recurrence and associated cost of management. Although BCG instillation for urothelial cancer treatment is the gold-standard treatment for this indication, repeated BCG treatments are associated with significant toxicity and failure, underlining the necessity for alternative or complementary immunotherapy and overall for better understanding of T-cell responses generated within bladder mucosa. Tumor-infiltrating lymphocytes (TIL) have long been recognized as a crucial component of the tumor microenvironment for the control of tumor. Among TIL, unconventional γδ T cells sparked interest due to their potent antitumor functions. Although preclinical mouse xenograft models demonstrated the relevance of using γδ T cells as a novel therapy for bladder cancer (BCa), the contribution of γδ T cells in BCa patients’ pathology remains unaddressed. Methods Therefore, we first determined the proportion of intratumor γδ T cells in muscle-invasive patients with BCa by deconvoluting data from The Cancer Genome Atlas (TCGA) and the frequency of blood Vδ1, Vδ2, and total γδ T cells, by flow cytometry, from 80 patients with BCa (40 non-muscle and 40 muscle-invasive patients with BCa), as well as from 20 age-matched non-tumor patients. Then we investigated in vitro which treatment may promote BCa tumor cell recognition by γδ T cells. Results We observed a decrease of γδ T-cell abundance in the tumor compared with corresponding normal adjacent tissue, suggesting that the tumor microenvironment may alter γδ T cells. Yet, high intratumor γδ T-cell proportions were significantly associated with better patient survival outcomes, potentially due to Vδ2 T cells. In the blood of patients with BCa, we observed a lower frequency of total γδ, Vδ1, and Vδ2 T cells compared with non-tumor patients, similarly to the TCGA analysis. In addition, a favorable clinical outcome is associated with a high frequency of circulating γδ T cells, which might be mainly attributed to the Vδ2 T-cell subset. Furthermore, in vitro assays revealed that either BCG, Zoledronate, or anti-BTN3 agonistic antibody treatment of bladder tumor cells induced Vδ2 T-cell cytolytic (CD107a+) and cytokine-production (IFN-γ and TNF-α). Strikingly, combining BCG and Zoledronate treatments significantly elicited the most quantitative and qualitative response by increasing the frequency and the polyfunctionality of bladder tumor-reactive Vδ2 T cells. Conclusions Overall, our results suggest that (1) Vδ2 T cells might play a prominent role in bladder tumor control and (2) non-muscle invasive patients with BCa undergoing BCG therapy may benefit from Zoledronate administration by boosting Vδ2 T cells’ antitumor activity.
Collapse
Affiliation(s)
- Sylvain Nguyen
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Mathieu F Chevalier
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.,INSERM U976, HIPI Unit (Human Immunology, Pathophysiology and Immunotherapy), Hôpital Saint-Louis, Paris, France
| | - Sulayman Benmerzoug
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Valérie Cesson
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Anna K Schneider
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Sonia-Cristina Rodrigues-Dias
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Florence Dartiguenave
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Ilaria Lucca
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Patrice Jichlinski
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Beat Roth
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Denise Nardelli-Haefliger
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Laurent Derré
- Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| |
Collapse
|
4
|
Rouanne M, Adam J, Radulescu C, Letourneur D, Bredel D, Mouraud S, Goubet AG, Leduc M, Chen N, Tan TZ, Signolle N, Bigorgne AE, Dussiot M, Tselikas L, Susini S, Danlos FX, Schneider AK, Chabanon RM, Vacher S, Bièche I, Lebret T, Allory Y, Soria JC, Arpaia N, Kroemer G, Kepp O, Thiery JP, Zitvogel L, Marabelle A. BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. J Clin Invest 2022; 132:145666. [PMID: 35503263 PMCID: PMC9197524 DOI: 10.1172/jci145666] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Accepted: 04/26/2022] [Indexed: 11/17/2022] Open
Abstract
Patients with high-risk non muscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical BCG therapy and may have a dismal outcome. Resistance mechanisms to such immunotherapy remain misunderstood. Here, using cancer cell lines, freshly resected human bladder tumors and cohorts of bladder cancer patients pre- and post-BCG therapy, we demonstrate two distinct patterns of immune subversion upon BCG relapse. In the first pattern, intracellular BCG infection of cancer cells induced a post-transcriptional downregulation of HLA-I membrane expression via an inhibition of the autophagy flux. Patients with HLA-I deficient cancer cells post-BCG therapy displayed a myeloid immunosuppressive tumor microenvironment with epithelial-to-mesenchymal transition (EMT) characteristics and dismal outcomes. Conversely, patients with HLA-I proficient cancer cells post-BCG therapy presented with CD8+ T cell tumor infiltrates, upregulation of inflammatory cytokines and inhibitory immune checkpoint molecules. Those patients had a very favorable outcome. We surmise that HLA-I expression in bladder cancers at relapse post-BCG does not result from immunoediting but rather from an immune subversion process directly induced by BCG on cancer cells, which predicts dismal prognosis. Cancer cells HLA-I scoring by immunohistochemistry (IHC) staining can be easily implemented by pathologists in routine practice in order to stratify future urothelial cancer patient treatment strategies.
Collapse
Affiliation(s)
| | - Julien Adam
- Inserm U1186, Gustave Roussy, Villejuif, France
| | | | | | | | | | | | - Marion Leduc
- Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France
| | - Noah Chen
- Department of Microbiology and Immunology, Columbia University, New York City, United States Minor Outlying Islands
| | - Tuan Zea Tan
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
| | | | | | | | | | | | | | | | | | - Sophie Vacher
- Department of Genetics, Pharmacogenomics Unit, Institut Curie, Paris, France
| | - Ivan Bièche
- Department of Genetics, Pharmacogenomics Unit, Institut Curie, Paris, France
| | | | - Yves Allory
- Department of Pathology, Hospital Foch, Suresnes, France
| | | | - Nicholas Arpaia
- Department of Microbiology and Immunology, Columbia University, New York City, United States Minor Outlying Islands
| | - Guido Kroemer
- Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France
| | - Oliver Kepp
- Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France
| | | | | | - Aurélien Marabelle
- Department of Therapeutic Innovation and Early Trials, Gustave Roussy, Villejuif, France
| |
Collapse
|
5
|
Benmerzoug S, Chevalier MF, Villier L, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients. EUR UROL SUPPL 2021; 34:79-82. [PMID: 34825225 PMCID: PMC8605422 DOI: 10.1016/j.euros.2021.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/15/2021] [Indexed: 01/03/2023] Open
Abstract
Aberrant glycosylation actively contributes to tumor progression and is a key hallmark of cancer. Most of the glycan moieties expressed on the surface of cancer cells are sialic acids that may modulate antitumor immune responses via binding to sialic acid–binding immunoglobulin-like lectins (Siglecs) expressed by immune cells. Here we show that Siglecs may decrease the bladder tumor immune response mediated by natural killer (NK) cells. We observed higher NK cell activity against desialylated bladder tumor cell lines. We therefore determined the expression of nine Siglecs on circulatory NK cells from healthy donors and patients with bladder cancer (BCa). NK cells from blood mainly express Siglec-7, which is highly upregulated in non–muscle-invasive BCa (NMIBC), as well as Siglec-6, albeit at a much lower level. However, both Siglecs are expressed by urinary NK cells from NMIBC patients undergoing bacillus Calmette-Guérin therapy. Ex vivo analysis of Siglec-6 and Siglec-7 expression levels on tumor-infiltrating NK cells (TINKs) from BCa patients showed that only Siglec-7 is expressed by TINKs. Finally, analyses for The Cancer Genome Atlas data set revealed that BCa patients with high expression levels of Siglec-7 have a poor survival rate. This work indicates that Siglec-7 may restrain NK-mediated antitumor immunity in BCa. Patient summary We investigated the expression of proteins called Siglecs in natural killer (NK) cells from patients with bladder cancer. We showed that levels of the protein Siglec-7 in blood, urine, and tumors from patients with bladder cancer are associated with poor clinical outcomes. Thus, Siglec-7 may be involved in the regulation of antitumor immunity mediated by NK cells in bladder cancer.
Collapse
Affiliation(s)
- Sulayman Benmerzoug
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Mathieu F Chevalier
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.,INSERM U976, Human Immunology, Pathophysiology and Immunotherapy Unit, Hôpital Saint-Louis, Paris, France.,Institut de Recherche Saint Louis, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Laura Villier
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Sylvain Nguyen
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Valérie Cesson
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Anna K Schneider
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Florence Dartiguenave
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Sonia-Christina Rodrigues-Dias
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Ilaria Lucca
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Patrice Jichlinski
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Beat Roth
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Denise Nardelli-Haefliger
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Laurent Derré
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
6
|
Rouanne M, Adam J, Radulescu C, Mouraud S, Bredel D, Letourneur D, Tan TZ, Signolle N, Bigorgne A, Dussiot M, Susini S, Tselikas L, Danlos FX, Chabanon R, Schneider AK, Vacher S, Lebret T, Bièche I, Allory Y, Soria JC, Thiery JP, Zitvogel L, Marabelle A. Abstract 66: BCG can subvert patients antitumor immune response by downregulating HLA-I expression on cancer cells. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Patients with high-risk non muscle-invasive bladder cancer (NMIBC) frequently relapse after standard BCG immunotherapy and have a dismal outcome after progression to muscle-invasive bladder cancer (MIBC). The mechanisms of tumor resistance to such immunotherapy remain elusive. We performed functional assays of fresh bladder tumors mixed with BCG, reinforced with in vitro experiments and in situ immune profiling of a cohort of MIBC pre- and post BCG therapy. Here, we demonstrate two distinct patterns of BCG-induced immune subversion. In the first pattern, intracellular BCG infection was associated with HLA-I loss and epithelial-to- mesenchymal transition (EMT) characteristics. HLA-I deficient tumors displayed a myeloid immunosuppressive microenvironment and dismal outcomes. Conversely, HLA-I+ BCG-treated tumors generated a Th1 type of immune response associated with an upregulation of exhaustion markers. Such patients had a very favorable outcome upon radical surgery. We surmise that HLA-I expression in bladder cancers does not result from immunoediting but rather from a BCG-induced EMT process that predicts dismal prognosis. Cancer cells HLA-I scoring by immunohistochemistry (IHC) staining can be easily implemented by pathologists in routine practice in order to stratify future urothelial cancer patient treatment strategies.
Citation Format: Mathieu Rouanne, Julien Adam, Camélia Radulescu, Séverine Mouraud, Delphine Bredel, Diane Letourneur, Tuan Zea Tan, Nicolas Signolle, Amélie Bigorgne, Michael Dussiot, Sandrine Susini, Lambros Tselikas, François-Xavier Danlos, Roman Chabanon, Anna K. Schneider, Sophie Vacher, Thierry Lebret, Ivan Bièche, Yves Allory, Jean-Charles Soria, Jean Paul Thiery, Laurence Zitvogel, Aurélien Marabelle. BCG can subvert patients antitumor immune response by downregulating HLA-I expression on cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 66.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Tuan Zea Tan
- 3Cancer Science Institute of Singapore, Singapore, Singapore
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Chevalier MF, Schneider AK, Cesson V, Dartiguenave F, Lucca I, Jichlinski P, Nardelli-Haefliger D, Derré L. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. Eur Urol 2018; 74:540-544. [DOI: 10.1016/j.eururo.2018.06.045] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 06/28/2018] [Indexed: 01/27/2023]
|
8
|
Schneider AK. An overview of RMP library activities: present and future. Bull Med Libr Assoc 1970; 58:316-9. [PMID: 5424511 PMCID: PMC197468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
The creation of the Regional Medical Programs has resulted in the origin of many library-related projects. Different regions have had a variety of projects. Surveys of resources in hospital libraries, continuing medical education surveys, and workshops for training hospital library personnel have been frequent. Instructional materials for library education have been developed or improved. Reference services have been stressed in many regions, and union lists of serials have been started. Grants for library projects total $1.4 million.
Collapse
|
9
|
Powers WE, Schneider AK, Shumate K, Fotenos H, Gallagher T. Evaluation of methods of computer estimation of interstitial and intracavitary dosimetry. Am J Roentgenol Radium Ther Nucl Med 1966; 96:59-65. [PMID: 5900890 DOI: 10.2214/ajr.96.1.59] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|